A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis
Latest Information Update: 16 Dec 2025
At a glance
- Drugs Galvokimig (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
Most Recent Events
- 16 Dec 2025 New trial record